Cargando…
Mycobacterium tuberculosis Rv3628 isan effective adjuvant via activationof dendritic cells for cancer immunotherapy
Tumor antigens (Ags) are weakly immunogenic and elicit inadequate immune responses, thus induction of antigen-specific immune activation via the maturation of dendritic cells (DCs) is a strategy used for cancer immunotherapy. In this study, we examined the effect of Rv3628 from Mycobacterium tubercu...
Autores principales: | Wu, Juan, Yang, Heng, Xu, Jin-chuan, Hu, Zhidong, Gu, Wen-fei, Chen, Zhen-yan, Xia, Jing-xian, Lowrie, Douglas B., Lu, Shui-Hua, Fan, Xiao-Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571481/ https://www.ncbi.nlm.nih.gov/pubmed/34786473 http://dx.doi.org/10.1016/j.omto.2021.10.003 |
Ejemplares similares
-
Protective Efficacy and Immunogenicity of Rv0351/Rv3628 Subunit Vaccine Formulated in Different Adjuvants Against Mycobacterium tuberculosis Infection
por: Kwon, Kee Woong, et al.
Publicado: (2023) -
Mycobacterium tuberculosis Rv3628 drives Th1-type T cell immunity via TLR2-mediated activation of dendritic cells and displays vaccine potential against the hyper-virulent Beijing K strain
por: Kim, Woo Sik, et al.
Publicado: (2016) -
A Potential Protein Adjuvant Derived from Mycobacterium tuberculosis Rv0652 Enhances Dendritic Cells-Based Tumor Immunotherapy
por: Lee, Seung Jun, et al.
Publicado: (2014) -
Potential of Mycobacterium tuberculosis chorismate mutase (Rv1885c) as a novel TLR4-mediated adjuvant for dendritic cell-based cancer immunotherapy
por: Jeong, Hyein, et al.
Publicado: (2022) -
Evaluation of Rv0220, Rv2958c, Rv2994 and Rv3347c of Mycobacterium tuberculosis for serodiagnosis of tuberculosis
por: You, Xiaolong, et al.
Publicado: (2017)